Nektar Therapeutics Forecast, price target & analysts
Nektar Therapeutics Target price 2026 - Analyst rating & recommendation
Nektar Therapeutics Classifications & Recommendation
Nektar Therapeutics Price Target
| Target Price | $154.02 |
| Price | $68.36 |
| Potential |
125.31%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Nektar Therapeutics 2027 .
The average Nektar Therapeutics target price is $154.02.
This is
125.31%
register free of charge
$201.60
194.91%
register free of charge
$80.80
18.20%
register free of charge
|
|
| A rating was issued by 18 analysts: 15 Analysts recommend Nektar Therapeutics to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Nektar Therapeutics stock has an average upside potential 2027 of
125.31%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 55.23 | 42.62 |
| 43.89% | 22.83% | |
| EBITDA Margin | -234.91% | -575.48% |
| 84.20% | 144.98% | |
| Net Margin | -297.08% | -668.21% |
| 145.81% | 124.92% |
14 Analysts have issued a sales forecast Nektar Therapeutics 2026 . The average Nektar Therapeutics sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Nektar Therapeutics EBITDA forecast 2026. The average Nektar Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Nektar Therapeutics Analysts have issued a net profit forecast 2026. The average Nektar Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -9.73 | -8.34 |
| 12.10% | 14.29% | |
| P/E | negative | |
| EV/Sales | 40.05 |
14 Analysts have issued a Nektar Therapeutics forecast for earnings per share. The average Nektar Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Nektar Therapeutics...
Current Nektar Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 21 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 22 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 11 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 08 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Apr 21 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Apr 21 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 21 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 22 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 11 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 08 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Apr 21 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Apr 21 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
